CSIMarket Company Name, Ticker, Customers, else..
 
Dermtech Inc   (NASDAQ: DMTK)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 35
 Employees 148
 Revenues (TTM) (Millions $) 14
 Net Income (TTM) (Millions $) -90
 Cash Flow (TTM) (Millions $) -20
 Capital Exp. (TTM) (Millions $) 0

Business Description


Dermtech Inc is a molecular dermatology company based in San Diego, California. The company focuses on developing non-invasive gene expression tests for the early detection of skin cancers and other skin-related conditions. Dermtech's proprietary technology allows for the collection and analysis of genomic information from skin samples, providing accurate and objective diagnostic information. The company's goal is to revolutionize the way dermatological diseases are detected and managed by providing physicians and patients with actionable information for personalized and targeted treatment decisions.


   Company Address: 12340 El Camino Real San Diego 92130 CA
   Company Phone Number: 450-4222   Stock Exchange / Ticker: NASDAQ DMTK


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
DGX   -3.89%    
EXAS        0.29% 
GH   -2.36%    
LH   -7.69%    
NTRA        0.06% 
VCYT   -7.81%    
• View Complete Report
   



Business Update

DermTech Sets Sights on Future Growth with Strategic Alternatives Exploration and Operational Streamlining

Published Fri, Apr 19 2024 8:11 AM UTC

In a recent press release, DermTech, a prominent player in precision dermatology leveraging non-invasive skin genomics technology, announced that its special committee of board directors has engaged TD Cowen to explore strategic alternatives with the goal of maximizing stockholder value. This move reflects the company s commitment to enhancing its position in the market and ...
Business Update

DermTech Ventures into New Strategies to Amplify Stockholder Value

Published Thu, Apr 18 2024 9:43 PM UTC

SAN DIEGO - DermTech, a trailblazer in precision dermatology, revealed today its plans to delve into strategic alternatives to increase stockholder value. The special committee of the company s board of directors has enlisted the expertise of TD Cowen to lead the exploration process. DermTech aims to leverage its groundbreaking non-invasive skin genomics technology to unlock...
Business Update

DermTech Implements Restructuring Measures to Enhance Revenue Growth and Operational Efficiency

Published Wed, Jan 31 2024 9:30 PM UTC

DermTech, a pioneering company in precision dermatology leveraging non-invasive skin genomics technology, has recently revealed its plans to implement additional restructuring measures. The is to prioritize revenue growth, streamline operations, and further reduce overall operating expenses. DermTech has diligently assessed its growth opportunities and operations, directing...
Product Service News

DermTech Melanoma Test Demonstrates High Accuracy Across All Skin Types in Real-World Clinical Study

Published Thu, Jan 18 2024 1:05 PM UTC

DermTech, Inc. (NASDAQ: DMTK), a leading provider of precision dermatology solutions powered by non-invasive skin genomics technology, recently announced positive topline results from two studies evaluating the DermTech Melanoma Test (DMT). These studies demonstrate the test s ability to accurately diagnose and rule out melanoma across all skin types in real-world clinical s...
Product Service News

Efficacy and Efficiency Enhanced: DermTech's Streamlined Approach to Melanoma Testing Marks a Turning Point in Non-Invasive Dermatology

Published Tue, Jan 16 2024 1:05 PM UTC

DermTech, a pioneering company in precision dermatology, has announced a significant development in their DermTech Melanoma Test (DMT). Effective March 1, 2024, the optional TERT promoter mutation add-on assay will be discontinued. This decision comes in light of multiple studies verifying the DMT s high negative predictive value (NPV) of 99% or higher. In this article, we w...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 3.11
Working Capital Ratio 3.53
Leverage Ratio (MRQ) 1.57
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -2.72 $
Revenues (TTM) 0.4 $
Cash Flow (TTM) -
Cash 1.12 $
Book Value 1.15 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 93,358
Net Income per Employee (TTM) -605,595
Receivable Turnover Ratio (TTM) 4.4
Inventory Turnover Ratio (TTM) 11.39
Asset Turnover Ratio (TTM) 0.09

Profitability Ratios Current
Gross Margin (MRQ) 19.2 %
Operating Margin (MRQ) -552.33 %
Net Margin (MRQ) -538.92 %
Net Cash Flow Margin (MRQ) -246.78 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.